Related references
Note: Only part of the references are listed.Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors
Ryunosuke Nakagawa et al.
FRONTIERS IN ONCOLOGY (2022)
The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection
Allen W. Zhang et al.
CLINICAL INFECTIOUS DISEASES (2022)
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
Hartmut Link et al.
SUPPORTIVE CARE IN CANCER (2021)
Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research Comment
Angioletta Lasagna et al.
IMMUNOTHERAPY (2021)
Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper
Tim Cooksley et al.
SUPPORTIVE CARE IN CANCER (2021)
Supportive care in patients with cancer during the COVID-19 pandemic
M. Aapro et al.
ESMO OPEN (2021)
A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis
Maria Sereno et al.
CANCERS (2021)
Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years
John Edelsberg et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death
Ramon Yarza et al.
EUROPEAN JOURNAL OF CANCER (2020)
RBC Transfusion Triggers: Is There Anything New?
Tina Tomic Mahecic et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2020)
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update
Julia Bohlius et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Anemia of Inflammation
Tomas Ganz
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor†
Maja D. Andersen et al.
LEUKEMIA & LYMPHOMA (2019)
Risk of pulmonary toxicity of bleomycin and filgrastim
Magali Laprise-Lachance et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim
Jeffrey J. Kirshner et al.
SUPPORTIVE CARE IN CANCER (2018)
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
T. Christopher Bond et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors
Edmond M. Kwan et al.
CLINICAL GENITOURINARY CANCER (2018)
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
M. Aapro et al.
ANNALS OF ONCOLOGY (2018)
Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor
Derek Weycker et al.
SUPPORTIVE CARE IN CANCER (2017)
The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review
Gary H. Lyman et al.
SUPPORTIVE CARE IN CANCER (2017)
Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals
Michael F. Leahy et al.
TRANSFUSION (2017)
Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
W. J. Heinz et al.
ANNALS OF HEMATOLOGY (2017)
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
J. Klastersky et al.
ANNALS OF ONCOLOGY (2016)
Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia
Irwin Gross et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Jeffrey L. Carson et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Long-term Survival With Paclitaxel and Gemcitabine for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant
Brian P. Mulherin et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2015)
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN
R. C. F. Leonard et al.
ANNALS OF ONCOLOGY (2015)
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy
G. H. Lyman et al.
ANNALS OF ONCOLOGY (2015)
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
Alena M. Pfeil et al.
SUPPORTIVE CARE IN CANCER (2015)
Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta-analysis and Systematic Review
Shelley R. Salpeter et al.
AMERICAN JOURNAL OF MEDICINE (2014)
Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data
J. Bohlius et al.
BRITISH JOURNAL OF CANCER (2014)
Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials
Anat Gafter-Gvili et al.
ACTA ONCOLOGICA (2013)
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Lisa K. Hicks et al.
BLOOD (2013)
Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia
Maureen J. Aarts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Transfusion Strategies for Acute Upper Gastrointestinal Bleeding
Candid Villanueva et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany
Hartmut Link et al.
ONKOLOGIE (2013)
Transfusion guidelines: when to transfuse
Zbigniew M. Szczepiorkowski et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base
Jeffrey J. Kirshner et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erythropoietin or darbepoetin for patients with cancer
Thomy Tonia et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?
Matti Aapro et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
Khaled M. Musallam et al.
LANCET (2011)
Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery
Jeffrey L. Carson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study
Frank V. Mortensen et al.
TRANSFUSION (2011)
Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies
Jorge J. Castillo et al.
BLOOD (2010)
Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
Laurent Bastit et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
Lionel Pinto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma
Eirini Katodritou et al.
ANNALS OF HEMATOLOGY (2007)
Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity
Christophe Bovy et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update
C. Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2007)
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC):: impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
M. Martin et al.
ANNALS OF ONCOLOGY (2006)
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
NM Kuderer et al.
CANCER (2006)
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
D Weycker et al.
ANNALS OF PHARMACOTHERAPY (2006)
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
CN Sternberg et al.
EUROPEAN JOURNAL OF CANCER (2006)
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors
GV Kondagunta et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy
J Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Medical progress: Anemia of chronic disease
G Weiss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prevalence and outcomes of anemia in cancer: A systematic review of the literature
K Knight et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial
M Auerbach et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:: a randomized, double-blind, placebo-controlled study
M Hedenus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
MD Green et al.
ANNALS OF ONCOLOGY (2003)
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
TJ Littlewood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)